Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Danne, T; Garg, S; Peters, AL; Buse, JB; Mathieu, C; Pettus, JH; Alexander, CM; Battelino, T; Ampudia-Blasco, FJ; Bode, BW; Cariou, B; Close, KL; Dandona, P; Dutta, S; Ferrannini, E; Fourlanos, S; Grunberger, G; Heller, SR; Henry, RR; Kurian, MJ; Kushner, JA; Oron, T; Parkin, CG; Pieber, TR; Rodbard, HW; Schatz, D; Skyler, JS; Tamborlane, WV; Yokote, K; Phillip, M.
International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors.
Diabetes Care. 2019; 42(6):1147-1154
PubMed FullText FullText_MUG


Autor/innen der Med Uni Graz:
Pieber Thomas

Dimensions Citations:

Plum Analytics:
Sodium-glucose cotransporter (SGLT) inhibitors are new oral antidiabetes medications shown to effectively reduce glycated hemoglobin (A1C) and glycemic variability, blood pressure, and body weight without intrinsic properties to cause hypoglycemia in people with type 1 diabetes. However, recent studies, particularly in individuals with type 1 diabetes, have demonstrated increases in the absolute risk of diabetic ketoacidosis (DKA). Some cases presented with near-normal blood glucose levels or mild hyperglycemia, complicating the recognition/diagnosis of DKA and potentially delaying treatment. Several SGLT inhibitors are currently under review by the U.S. Food and Drug Administration and European regulatory agencies as adjuncts to insulin therapy in people with type 1 diabetes. Strategies must be developed and disseminated to the medical community to mitigate the associated DKA risk. This Consensus Report reviews current data regarding SGLT inhibitor use and provides recommendations to enhance the safety of SGLT inhibitors in people with type 1 diabetes. © 2019 by the American Diabetes Association.

© Meduni Graz Impressum